The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...